SRSF7 is a serine/arginine-rich splicing factor with multifaceted roles in RNA processing and disease pathogenesis. Functionally, SRSF7 regulates pre-mRNA splicing and modulates alternative splicing events 1, including control of pyruvate kinase (PKM) splicing and stathmin-2 (STMN2) expression 2. Beyond canonical splicing, SRSF7 enhances pri-miRNA cleavage by Microprocessor through recognition of specific RNA motifs and secondary structures 3, and acts as a transcriptional co-activator of interferon regulatory factor 7 (IRF7) via STAT1 and histone methyltransferase cooperation 4. SRSF7 also regulates N6-methyladenosine (m6A) deposition on target mRNAs, promoting glioblastoma cell proliferation and migration 5. Disease relevance is substantial across multiple contexts. SRSF7 upregulation in idiopathic pulmonary fibrosis (IPF) drives fibroblast metabolic dysregulation and pathological collagen accumulation through PKM alternative splicing 1. In pancreatic cancer, the cALG8/CLK1/SRSF7 axis promotes gemcitabine resistance by regulating ATM alternative splicing to enhance DNA damage repair 6. In ALS/FTD, poly-PR dipeptide repeats perturb SRSF7 function, reducing STMN2 expression and impairing axonal regeneration 2. SRSF7 also mediates host-specific antiviral responses, with human SRSF7 inhibiting influenza polymerase activity through a conserved amino acid motif absent in avian orthologs 7. Therapeutically, SRSF7 represents a promising drug target, with lomitapide identified as an SRSF7 modulator reducing experimental pulmonary fibrosis 1, and antisense oligonucleotides targeting the CLK1/SRSF7 axis enhancing chemotherapy and immunotherapy efficacy in pancreatic cancer 6.